Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its price target reduced by equities research analysts at JPMorgan Chase & Co. from $12.00 to $8.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 112.20% from […]
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […]
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call.
Allspring Global Investments Holdings LLC raised its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) by 468.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,267 shares of the company’s stock after purchasing an additional 9,286 shares during the […]